Ph. Eur. 3.2.9 (EP 3.2.9): Rubber Closures for Aqueous Parenteral Preparations
Ph. Eur. 3.2.9, also written EP 3.2.9 or Ph.Eur. 3.2.9, is the European Pharmacopoeia general chapter that sets the requirements for rubber closures used on containers of aqueous parenteral preparations, powders and freeze-dried powders. It is published by the European Directorate for the Quality of Medicines and HealthCare (EDQM), the revised text has applied since 1 April 2023, and it is mandatory for aqueous parenteral preparations in Europe. It requires a closure to pass identification, chemical tests on an aqueous extract and functional tests for penetrability, fragmentation and self-sealing; it sets no tensile strength requirement.
This guide covers the names buyers use for the chapter, what it requires and what the 2023 revision changed, the tensile strength, fragmentation and extractables questions, what a closure supplier has to demonstrate, and how the chapter relates to the aluminium seal and to the USP chapters.
Key takeaways
- EP 3.2.9, Ph. Eur. 3.2.9, EU Ph 3.2.9 and European Pharmacopoeia 3.2.9 all name one chapter: “Rubber closures for containers for aqueous parenteral preparations, for powders and for freeze-dried powders.”
- It is mandatory for aqueous parenteral preparations because the legally binding monographs on Pharmaceutical preparations (2619) and Parenteral preparations (0520) refer to it.
- The revised chapter was published in Ph. Eur. Supplement 11.1 with an implementation date of 1 April 2023, adding coated closures, bi-layer seals and lubricated closures.
- Chemical tests run on an aqueous extract of the closures; the revision removed the extractable heavy metals test in line with ICH Q3D and kept extractable zinc.
- Functional tests cover penetrability, fragmentation and self-sealing, and the revision says when each should be performed, adapted or omitted.
- The chapter sets no tensile strength limit; tensile strength, hardness and compression set belong in the compound specification.
- It governs the rubber stopper, not the aluminium seal crimped over it, and is the European counterpart of USP <381> and USP <382>.
EP 3.2.9, Ph. Eur. 3.2.9 and the other names for the same chapter
Every spelling below refers to the same European Pharmacopoeia general chapter; the differences are abbreviation habits, not different documents.
| How it is written | What it stands for |
|---|---|
| Ph. Eur. 3.2.9, Ph.Eur. 3.2.9, Ph Eur 3.2.9 | The EDQM’s own abbreviation, Pharmacopoeia Europaea |
| EP 3.2.9, EP3.2.9 | European Pharmacopoeia, the common English shorthand |
| EU Ph 3.2.9, EU.Ph 3.2.9, Pharm. Eur. 3.2.9 | Informal variants of the same abbreviation |
| European Pharmacopoeia general chapter 3.2.9 | The full form |
| 30209 | The text number the Pharmacopoeia prints above the chapter, preceded by a date, as in 01/2008:30209 on the 2008 text |
The number places the chapter in the book: section 3 covers materials and containers, 3.2 covers containers, and 3.2.9 is the rubber closures chapter within it. When a specification cites “EP 3.2.9” it should also state which edition or supplement applies, because the 2023 revision changed the tests.
What is Ph. Eur. 3.2.9?
Ph. Eur. 3.2.9 is the European Pharmacopoeia general chapter that specifies the material requirements and test methods for rubber (elastomeric) closures used with injectable containers. It is published by the European Directorate for the Quality of Medicines and HealthCare (EDQM), the body that maintains the European Pharmacopoeia.
A rubber closure, or elastomeric closure, is the stopper that seats in the vial neck and forms the primary seal against the drug; the aluminium or aluminium-plastic seal is then crimped over it to hold it compressed. Because the closure is in direct and prolonged contact with a sterile injectable, it must not release harmful substances, must reseal after needle penetration where the container is multidose, and must be compatible with the product. Ph. Eur. 3.2.9 defines what the closure material must meet and the tests used to show it. The chapter is mandatory for aqueous parenteral preparations in Europe because it is cross-referenced by legally binding general monographs, so it functions as a compliance requirement, not just guidance. The freeze-dried case is the demanding one, because a lyophilised product is stoppered inside the dryer and the closure has to seat correctly in two positions.
What Ph. Eur. 3.2.9 requires
Ph. Eur. 3.2.9 requires a rubber closure to be chemically suitable, identifiable against the closure used in compatibility testing, and functionally sound for the way it will be pierced. The closures are made by vulcanising (cross-linking) elastomers with suitable additives, and the chapter tests what those materials release and how the closure behaves.
| Requirement area | What the chapter covers | What the 2023 revision changed |
|---|---|---|
| Scope | Rubber closures for aqueous parenterals, powders and freeze-dried powders | Coated closures, bi-layer seals and lubricated closures added |
| Materials | Elastomers vulcanised with additives; natural rubber latex not permitted | Dry natural rubber confirmed as usable, because allergenic proteins are removed in processing |
| Closure types | Type I closures meet the strictest chemical requirements; type II closures have mechanical properties for special uses such as multiple piercing | Not among the reported changes |
| Compatibility | The closure must not adsorb product components or release substances that affect the preparation, throughout its shelf life | A change in closure composition now calls for a risk assessment of whether compatibility testing must be repeated |
| Identification | Confirms the closure is an elastomer and helps detect a difference from the closures used in compatibility testing | Infrared spectroscopy remains the main technique; total ash became complementary |
| Chemical tests | Run on solution S, an aqueous extract prepared by autoclaving the closures in water: tests such as appearance, acidity or alkalinity, absorbance, reducing substances and extractable zinc | Extractable heavy metals test removed, aligning with ICH Q3D; extractable zinc retained |
| Functional tests | Penetrability, fragmentation, and self-sealing for closures on multidose containers | Introduction expanded on when to perform, adapt or omit each test; fragmentation procedure for dry preparations and a 16-hour standing step deleted |
The limits that go with each test are set in the chapter text itself, which is available from the EDQM by subscription. They are not reproduced here, because a limit quoted from an old edition is exactly the kind of number that ends up in a specification after it has changed. Animal-derived processing aids inside the compound are a separate question, assessed under BSE/TSE compliance. Dimensions and forms for the same closures are set separately, by ISO 8362-2.
Tensile strength, fragmentation and extractables
These are the three requirements buyers ask about most, and the chapter treats them very differently: it sets no tensile strength test, a functional fragmentation test, and a screening set of chemical tests that is not a full extractables study.
Tensile strength. Ph. Eur. 3.2.9 does not set a tensile strength requirement, and neither the published chapter nor the EDQM’s account of the 2023 revision describes one. The chapter judges mechanical behaviour through function: whether a needle passes through at an acceptable force, whether it tears rubber fragments loose, and whether the closure reseals. Tensile strength, elongation at break, hardness and compression set are properties of the rubber compound. They belong in the stopper specification agreed with the supplier, where they are controlled lot to lot, not in a claim of 3.2.9 compliance.
Fragmentation. The fragmentation test pierces closures with a needle under defined conditions and counts the rubber fragments released, against a limit in the chapter. It matters because fragments (coring) end up as particles in an injectable. The 2023 revision removed the separate procedure for closures on dry preparations and dropped a 16-hour standing step, and it now says when the test can be adapted or omitted for a closure that is not pierced in use. In the US, the equivalent fragmentation test sits in USP <381>.
Extractables. The chemical tests on solution S screen what a closure releases into hot water: acidity or alkalinity, UV absorbance, reducing substances, extractable zinc and similar. They show a compound is broadly clean. They are not a product-specific extractables and leachables assessment, which looks for what migrates into the actual drug under its storage conditions, and which the drug maker runs separately; the approach is set out under extractables and leachables. With the heavy metals test removed, elemental impurities are handled through the ICH Q3D risk assessment for the drug product rather than by a closure test.
What a closure has to demonstrate
To show a stopper meets Ph. Eur. 3.2.9 for a given product, the evidence comes from both the closure supplier and the drug maker.
| Evidence | Who provides it | Why it matters |
|---|---|---|
| A statement of compliance with Ph. Eur. 3.2.9, naming the closure type (I or II) and the edition | Closure supplier | Fixes which version of the tests applies |
| Results of the chemical tests on solution S | Closure supplier | Shows the compound passes the extract tests |
| Functional test results for the intended use: penetrability, fragmentation, self-sealing where multidose | Closure supplier, or the drug maker with the actual needle and fill | The revision lets these be adapted to the container, so the conditions must be stated |
| An assurance that the composition does not change, and notice if it does | Closure supplier | Triggers the risk assessment on repeating compatibility testing |
| Compatibility with the preparation over its shelf life | Drug maker | The chapter requires it and only the product itself can show it |
| A product-specific extractables and leachables assessment | Drug maker, with supplier data | Goes beyond the screening tests in the chapter |
| Latex and BSE/TSE status | Closure supplier | Natural rubber latex is not permitted; animal-origin materials are assessed separately |
A buyer who asks for “EP 3.2.9 compliance” and receives only a one-line certificate has the first row of this table. The rest is what a qualification file for an EU filing needs.
How 3.2.9 relates to the aluminium seal
Ph. Eur. 3.2.9 governs the rubber closure; the aluminium or aluminium-plastic seal that crimps over it is a separate component with its own material and dimensional requirements. In a vial closure system three parts work together: the glass vial, the rubber stopper and the metal seal. The stopper forms the seal against the drug and is what 3.2.9 controls. The aluminium seal then crimps under the vial neck flange to hold the stopper compressed, maintaining the container closure integrity of the pack. The seal’s own conformity comes from its aluminium and plastic material specifications and its dimensioning to the vial neck, covered by the ISO 8362 series. The two components are qualified separately but must be compatible, since the seal has to keep the 3.2.9-compliant closure correctly seated for the life of the product.
Ph. Eur. 3.2.9 vs the USP chapters and ISO 8871
Ph. Eur. 3.2.9 is the European requirement for rubber closures; USP <381> and USP <382> are the corresponding United States chapters, and the ISO 8871 series is the international standard family for the same parts. They pursue the same goal, a clean and functional elastomeric closure, through comparable but not identical tests, so a closure sold into several markets is usually characterised against all of them.
| Region | Reference | Scope |
|---|---|---|
| Europe | Ph. Eur. 3.2.9 | Rubber closures for aqueous parenteral preparations, powders and freeze-dried powders: chemical and functional tests |
| United States | USP <381> | Elastomeric components in injectable packaging: physicochemical and biological tests, and fragmentation |
| United States | USP <382> | Elastomeric component functional suitability, including penetrability and self-sealing |
| International | ISO 8871 series | Elastomeric parts for parenterals: extractables in aqueous autoclavates (Part 1) to functional requirements and testing (Part 5) |
A drug maker exporting to Europe and the US typically qualifies its stopper against Ph. Eur. 3.2.9 and both USP chapters, and separately qualifies the aluminium seal that crimps over it. The compound choice behind the stopper, most often chlorobutyl or bromobutyl for injectables, is compared in chlorobutyl vs bromobutyl stoppers.
How this works in practice at Autofits
Ph. Eur. 3.2.9 is a requirement on the stopper, and the stopper comes from the drug maker’s own qualified closure supplier. Autofits makes the component that goes over it: the aluminium or aluminium-plastic seal that crimps under the vial neck flange and keeps a 3.2.9-compliant stopper compressed and correctly seated for the life of the product. What a seal supplier contributes to an EU filing is therefore a seal matched to the stopper’s nominal size and to the vial neck, made from declared materials.
The range covers FlipTop Optima flip-off seals in 13, 20, 28, 32 and 34 mm, tear-off and tear-down aluminium seals, and aluminium pilfer-proof (ROPP) caps. The seals are made from AA8011 aluminium alloy, epoxy lacquer conforming to 21 CFR 175.300 and polypropylene conforming to 21 CFR 177.1520, with heavy metals held to a maximum 100 ppm total and BSE/TSE-free status. Production runs under an ISO 15378:2017 quality system, alongside ISO 9001:2015 and ISO 14001:2015 certification, a Drug Master File (DMF 18100) and a CFDA registration, in a 75,000 sq ft facility in Nashik, India, with an ISO Class 8 cleanroom and 100% high-speed camera inspection. To match a seal to a qualified stopper, the stopper’s nominal size and seated height and the vial neck finish are what the seal specification starts from.
Frequently asked questions
What does Ph. Eur. 3.2.9 cover?
Ph. Eur. 3.2.9 sets the material requirements and test methods for rubber (elastomeric) closures used to seal containers of aqueous parenteral preparations, powders and freeze-dried powders. It covers identification, chemical tests on an aqueous extract and functional tests for penetrability, fragmentation and self-sealing. It governs the rubber stopper, not the metal seal crimped over it.
Is EP 3.2.9 the same as Ph. Eur. 3.2.9?
Yes. EP 3.2.9, Ph. Eur. 3.2.9, Ph.Eur. 3.2.9 and EU Ph 3.2.9 are different abbreviations for the same European Pharmacopoeia general chapter on rubber closures. A specification that cites any of them should also state the edition or supplement, because the revised chapter has applied since 1 April 2023.
Which tests are covered by EP 3.2.9?
The chapter covers identification of the closure, chemical tests on an aqueous extract (solution S) such as appearance, acidity or alkalinity, absorbance, reducing substances and extractable zinc, and functional tests for penetrability, fragmentation and self-sealing. The 2023 revision removed the extractable heavy metals test in line with ICH Q3D.
Does Ph. Eur. 3.2.9 set a tensile strength requirement for rubber closures?
No. Ph. Eur. 3.2.9 judges mechanical behaviour through functional tests for penetrability, fragmentation and self-sealing, and sets no tensile strength limit. Tensile strength, elongation, hardness and compression set are compound properties agreed in the stopper specification between the buyer and the closure supplier.
Is Ph. Eur. 3.2.9 mandatory?
Yes, for aqueous parenteral preparations in Europe. The chapter is referred to in the legally binding general monograph on Pharmaceutical preparations (2619) and the dosage form monograph Parenteral preparations (0520), which makes compliance a requirement rather than guidance. Confirm current text and applicability with the EDQM.
When was Ph. Eur. 3.2.9 last revised?
The revised chapter was published in Ph. Eur. Supplement 11.1 with an implementation date of 1 April 2023. The revision added coated closures, bi-layer seals and lubricated closures, removed the extractable heavy metals test, deleted the fragmentation procedure for dry preparations, and clarified when functional tests can be adapted or omitted.
Does Ph. Eur. 3.2.9 apply to the aluminium seal?
No. Ph. Eur. 3.2.9 applies to the rubber closure. The aluminium or aluminium-plastic seal crimped over the closure is a separate component, qualified through its own material specifications and its dimensioning to the vial neck. The two components must be compatible so the seal keeps the compliant closure correctly seated.
Related reading
- USP <381>: elastomeric closures for injections
- USP <382>: elastomeric closure functional suitability
- Extractables and leachables in packaging
- Elastomeric closure: definition
- ISO 8362-2: closures for injection vials
- USP <1207>: container closure integrity
- Flip-off seal: definition
- The revised USP <382> testing requirements
Sources
- EDQM: Revised general chapter on rubber closures published in the Ph. Eur. Supplement 11.1 (https://www.edqm.eu/en/-/revised-general-chapter-on-rubber-closures-published-in-the-ph.-eur.-supplement-11.1)
- European Pharmacopoeia: general chapter 3.2.9, Rubber closures for containers for aqueous parenteral preparations, for powders and for freeze-dried powders (https://www.edqm.eu/en/european-pharmacopoeia)
- ECA Academy: Revised Ph. Eur. Chapter 3.2.9. Rubber Closures, summary of the Supplement 11.1 changes (https://www.gmp-compliance.org/gmp-news/revised-ph-eur-chapter-on-rubber-closures)
- ICH: Q3D, Guideline for Elemental Impurities (https://www.ich.org/)
- USP-NF: General Chapters <381> and <382>, Elastomeric Components in Injectable Pharmaceutical Product Packaging/Delivery Systems and Elastomeric Component Functional Suitability (https://www.uspnf.com/)
- ISO: ISO 8871-5, Elastomeric parts for parenterals and for devices for pharmaceutical use, Part 5: Functional requirements and testing (https://www.iso.org/standard/85863.html)
*Last updated: 2026-09-15. This article is general regulatory information, not legal or compliance advice; confirm current regulatory text, test limits and requirements with the EDQM and the European Pharmacopoeia.*
